Vigil Neuroscience Inc. (VIGL)
1.82
0.02 (1.11%)
At close: Apr 23, 2025, 3:59 PM
1.81
-0.45%
Pre-market: Apr 24, 2025, 04:00 AM EDT
1.11% (1D)
| Bid | 1.75 |
| Market Cap | 84.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -84.26M |
| EPS (ttm) | -2.07 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | -1.09 |
| Analyst | Buy |
| Ask | 1.89 |
| Volume | 63,917 |
| Avg. Volume (20D) | 318,486 |
| Open | 1.81 |
| Previous Close | 1.80 |
| Day's Range | 1.79 - 1.86 |
| 52-Week Range | 1.31 - 6.06 |
| Beta | 1.95 |
About VIGL
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy wi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 69
Stock Exchange NASDAQ
Ticker Symbol VIGL
Website https://www.vigilneuro.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 669.23% from the latest price.
Stock Forecasts3 weeks ago
-6.81%
Vigil Neuroscience shares are trading lower. The c...
Unlock content with
Pro Subscription
1 month ago
-10.21%
Vigil Neuroscience shares are trading lower after the company a Q4 GAAP EPS miss.
